Holmes Biopharma, Inc.: January Highest Month of Sales to Date
February 05 2008 - 9:00AM
Marketwired
SCOTTSDALE, ARIZONA announces January sales for its Phase I
operation in Omaha, Nebraska have reached 3 Million in awarded
contracts. Furthermore, the Company expects to be operating the
Omaha facility at full capacity through to June 2008 and
anticipates this trend to continue.
"Traditionally, January is one of the slowest months of the year
in sales activity and with surpassing our previous sales records we
are succeeding in realizing our growth expectations," stated John
Metcalfe, President and CEO, Holmes Biopharma, Inc.
About Holmes:
Holmes Biopharma, Inc. and it's wholly owned subsidiary, Qualia
Clinical Service, Inc. is a contract research organization focused
on providing integrated and cost effective clinical development
services. Currently, clinics operate in Omaha, Nebraska USA,
Toronto, Canada and Kiev, Ukraine, eastern Europe. For more
information about the company please visit our website at
www.holmesbiopharma.com.
On behalf of the Board of Directors
John F. Metcalfe, President and CEO
Certain statements in this press release constitute "forward
looking statements" within the meaning of the United States
Securities Legislation. The Company's actual results could differ
from those in the forward-looking statements. Do not construe this
information as investment advice. This is not a solicitation to buy
or sell securities. This does not purport to be a complete analysis
of the Company. Investing in securities is speculative and carries
a high degree of risk. Past performance does not guarantee future
results. Readers should consult their own independent advisers with
any investment, including any contemplated investment. All
information contained in this press release should be independently
investigated. This press release contains forward-looking
statements. These remarks involve risks and uncertainties. Risks
are not limited to quarterly fluctuations in results or the
companies' management of growth and competition. Other risks are
detailed in the Company's SEC filings. Actual results may differ
materially from such information set forth herein.
Contacts: Holmes Biopharma, Inc. John F. Metcalfe President and
CEO 1-800-778-4990 Email: ir@holmesbiopharma.com Website:
www.holmesbiopharma.com
Swiftsure (CE) (USOTC:HLMB)
Historical Stock Chart
From Apr 2024 to May 2024
Swiftsure (CE) (USOTC:HLMB)
Historical Stock Chart
From May 2023 to May 2024